JP2020503289A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503289A5
JP2020503289A5 JP2019531463A JP2019531463A JP2020503289A5 JP 2020503289 A5 JP2020503289 A5 JP 2020503289A5 JP 2019531463 A JP2019531463 A JP 2019531463A JP 2019531463 A JP2019531463 A JP 2019531463A JP 2020503289 A5 JP2020503289 A5 JP 2020503289A5
Authority
JP
Japan
Prior art keywords
conjugate
compound
pharmaceutical composition
group
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019531463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/066361 external-priority patent/WO2018112176A1/en
Publication of JP2020503289A publication Critical patent/JP2020503289A/ja
Publication of JP2020503289A5 publication Critical patent/JP2020503289A5/ja
Pending legal-status Critical Current

Links

JP2019531463A 2016-12-14 2017-12-14 Hsp90標的化コンジュゲート及びその製剤 Pending JP2020503289A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662434282P 2016-12-14 2016-12-14
US62/434,282 2016-12-14
US201762449260P 2017-01-23 2017-01-23
US62/449,260 2017-01-23
US201762487726P 2017-04-20 2017-04-20
US62/487,726 2017-04-20
PCT/US2017/066361 WO2018112176A1 (en) 2016-12-14 2017-12-14 Hsp90-targeting conjugates and formulations thereof

Publications (2)

Publication Number Publication Date
JP2020503289A JP2020503289A (ja) 2020-01-30
JP2020503289A5 true JP2020503289A5 (enExample) 2021-01-21

Family

ID=62559344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531463A Pending JP2020503289A (ja) 2016-12-14 2017-12-14 Hsp90標的化コンジュゲート及びその製剤

Country Status (7)

Country Link
US (2) US11241500B2 (enExample)
EP (1) EP3554558A4 (enExample)
JP (1) JP2020503289A (enExample)
CN (1) CN110049783A (enExample)
AU (1) AU2017376766A1 (enExample)
CA (1) CA3045041A1 (enExample)
WO (1) WO2018112176A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
EP3723811A4 (en) * 2017-12-14 2021-09-01 Tarveda Therapeutics, Inc. TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER
US20220031853A1 (en) * 2018-09-14 2022-02-03 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CN109400597B (zh) * 2018-11-08 2020-07-28 西安交通大学 一种基于vegfr-2抑制剂abt-869的蛋白降解靶向嵌合体及制备方法和应用
KR20210148157A (ko) * 2019-04-03 2021-12-07 타베다 세라퓨틱스, 인코포레이티드 Hsp90-결합 접합체 및 이의 제형
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
CN112279863A (zh) * 2019-07-25 2021-01-29 华东师范大学 Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用
TW202222311A (zh) * 2020-08-26 2022-06-16 美商塔維達治療公司 結合熱休克蛋白90(hsp90)之共軛體和彼之調製劑
CN112168825A (zh) * 2020-10-30 2021-01-05 江苏大学 含hsp90抑制剂和parp抑制剂的药物组合物
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
CN115286643B (zh) * 2022-09-02 2023-09-01 南京大学 蛋白质靶向降解化合物及其制备方法和应用
WO2025166213A1 (en) * 2024-02-01 2025-08-07 Fulgent Pharma Llc Treatment of head and neck cancer with pharmaceutical composition comprising nanoparticles containing taxane
WO2025214403A1 (zh) * 2024-04-12 2025-10-16 四川科伦博泰生物医药股份有限公司 抗体药物偶联物、组合物及其用途和方法
WO2025249944A1 (ko) * 2024-05-29 2025-12-04 주식회사 매직불릿테라퓨틱스 열충격 단백질 조절 접합체 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2004029055A1 (en) 2002-09-30 2004-04-08 Bayer Pharmaceuticals Corporation Fused azole-pyrimidine derivatives
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2663401C (en) * 2006-09-15 2011-07-12 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
HK1217085A1 (zh) * 2012-12-28 2016-12-23 Tarveda Therapeutics, Inc 包封在顆粒中的靶向綴合物及其製劑
EP3164420A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3791897A1 (en) * 2016-02-29 2021-03-17 Madrigal Pharmaceuticals, Inc. Hsp90 inhibitor drug conjugates

Similar Documents

Publication Publication Date Title
Sanches et al. Is prodrug design an approach to increase water solubility?
ES2622471T3 (es) Compuestos y procedimientos para la administración de análogos de prostaciclina
AU2009210655B2 (en) Treatment of bladder diseases with a TLR7 activator
ES2637266T3 (es) Derivados fumarato de ácido graso y sus usos
Apostolidou et al. Treatment of acute lymphoblastic leukaemia: a new era
JP2019104739A (ja) Sn−38の徐放性コンジュゲート
US20100010059A1 (en) Anticancer oral formulation
JP2013519653A5 (enExample)
KR20140022750A (ko) 디안하이드로갈락티톨 및 디아세틸디안하이드로갈락티톨과 같은 치환된 헥시톨을 포함하는 준최적하게 투여되는 화학적 화합물의 치료상 이점을 향상시키기 위한 조성물 및 방법
CN104768931A (zh) 化合物及其治疗用途
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
US10759803B2 (en) Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto
Zhan et al. Discovery of 6-(difluoro (6-(4-fluorophenyl)-[1, 2, 4] triazolo [4, 3-b][1, 2, 4] triazin-3-yl) methyl) quinoline as a highly potent and selective c-Met inhibitor
JP2014532727A (ja) 疎水性カンプトテシン誘導体の医薬組成物
US20050130882A1 (en) Combination therapy including 9-nitro-20(S)-camptothecin
Yan et al. Discovery of 4-phenyl-2H-benzo [b][1, 4] oxazin-3 (4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors
Zheng et al. Design, synthesis and bioevaluation of PI3Kα-selective inhibitors as potential colorectal cancer drugs
US20220040194A1 (en) Use of olanzapine for treatment of parp-inhibitor-induced nausea
CN101437505A (zh) 去甲二氢愈创木酸衍生物在治疗抗药性癌症、病毒和微生物感染中的用途
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
TWI638825B (zh) 抑制癌症及病毒之化合物
Wang et al. Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue
CN119950749A (zh) 基于聚合物的大分子前药
AU2021378944A1 (en) Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer
JPWO2007023778A1 (ja) 新規抗癌併用薬